Home › Funds › Bellevue Group AG › VRDN
Bellevue Group AG position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
Bellevue Group AG reported holding 7,109,318 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$146.4M, representing 3.04% of its reported portfolio and ranking #8 among its reported holdings. Bellevue Group AG has disclosed VRDN holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's VRDN position evolved
Bellevue Group AG first disclosed a stake in VRDN in Q3 2023 at 63,770 shares (US$978K). The position peaked in Q3 2026 at 7,109,318 shares, worth US$146.4M. Across 7 filings, Bellevue Group AG increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 7,109,318 shares valued at US$146.4M — an increase of 377,409 shares quarter over quarter.. Notable position changes include a 53% trim in Q4 2023 (shares fell 20% over the following quarter), a 36% trim in Q1 2024 (shares fell 26% over the following quarter), a 54% increase in Q1 2026 (shares fell 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 63.77K | $978.23K | New |
| Q4 2023 | 30.00K | $653.40K | Reduce |
| Q1 2024 | 19.10K | $334.44K | Reduce |
| Q4 2025 | 4.36M | $135.64M | New |
| Q1 2026 | 6.73M | $131.56M | Add |
| Q2 2026 | 6.73M | $123.67M | Hold |
| Q3 2026 | 7.11M | $146.38M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 40 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Kynam Capital Management, LP (US$126.6M), Fairmount Funds Management LLC (US$104.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Paradigm Biocapital Advisors LP 12.41M sh · $227.08M · Q3 2026
- Kynam Capital Management, LP 6.15M sh · $126.59M · Q3 2026
- Fairmount Funds Management LLC 5.09M sh · $104.82M · Q3 2026
- RTW INVESTMENTS, LP 4.98M sh · $102.03M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 5.96M sh · $81.79M · Q3 2026
- Novo Holdings A/S 4.87M sh · $78.92M · Q3 2026
- Venrock Adviser, LLC 3.26M sh · $67.08M · Q3 2026
- Deep Track Capital, LP 3.83M sh · $64.34M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 4.50M sh · $61.83M · Q3 2026
- Caligan Partners LP 3.08M sh · $57.34M · Q3 2026
- Context Capital Management, LLC 49.00M sh · $56.47M · Q3 2026
- Avoro Capital Advisors LLC 2.50M sh · $51.48M · Q3 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held VRDN?
Bellevue Group AG has disclosed VRDN holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
What is Bellevue Group AG's current position in VRDN?
As of Q3 2026, Bellevue Group AG holds 7.11M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $146.38M, representing 3.04% of its reported portfolio and ranking #8.
Has Bellevue Group AG been buying or selling VRDN?
In the latest 13F filing (Q3 2026), Bellevue Group AG increased its position in VRDN. The position peaked in Q3 2026 at 7.11M shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, Fairmount Funds Management LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.